{"id":"parenteral-oral-methadone-ratio-1-2","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Sedation"},{"rate":"15-25","effect":"Sweating"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"QT prolongation"},{"rate":"10-20","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL651","moleculeType":"Small molecule","molecularWeight":"309.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methadone acts as a full mu opioid receptor agonist with a long half-life (24-36 hours), allowing once-daily dosing for opioid maintenance therapy. The parenteral-to-oral ratio of 1:2 reflects the relative bioavailability differences between intravenous/intramuscular and oral administration routes. This formulation is used in opioid substitution treatment programs to prevent withdrawal and reduce illicit opioid use.","oneSentence":"Methadone is a synthetic opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and suppress withdrawal symptoms in opioid-dependent patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:32.812Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"},{"name":"Chronic pain management"},{"name":"Prevention of opioid withdrawal symptoms"}]},"trialDetails":[{"nctId":"NCT01836328","phase":"PHASE3","title":"Conversion From Parenteral to Oral Methadone.","status":"COMPLETED","sponsor":"L'Hospitalet de Llobregat","startDate":"2011-08","conditions":"Pain","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eptadone (1mg/ml) oral solution"],"phase":"phase_3","status":"active","brandName":"Parenteral /oral methadone ratio 1:2","genericName":"Parenteral /oral methadone ratio 1:2","companyName":"L'Hospitalet de Llobregat","companyId":"l-hospitalet-de-llobregat","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methadone is a synthetic opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and suppress withdrawal symptoms in opioid-dependent patients. Used for Opioid use disorder maintenance treatment, Chronic pain management, Prevention of opioid withdrawal symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}